Last reviewed · How we verify
Mycobutin
At a glance
| Generic name | Mycobutin |
|---|---|
| Sponsor | Harriet Shezi Children's Clinic |
| Target | Bacterial DNA-directed RNA polymerase, DNA-directed RNA polymerase subunit beta |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Pulmonary Mycobacterium avium complex infection
Common side effects
- Nausea
- Abdominal Pain
- Headache
- Diarrhea
- Dyspepsia
- Eructation
- Flatulence
- Fever
- Pain
- Chest Pain
- Asthenia
- Vomiting
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults (PHASE1)
- A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004) (PHASE1)
- Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
- A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) (PHASE2, PHASE3)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Short-course Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2, PHASE3)
- Rescue Therapy for Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycobutin CI brief — competitive landscape report
- Mycobutin updates RSS · CI watch RSS
- Harriet Shezi Children's Clinic portfolio CI